Vivos Therapeutics, Inc. VVOS
0.14
(0.01)
(6.67%)
as of 25 Sep
- Market cap
- $4.9M
- P/E
- 0.0×
Follow VVOS
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 8.76 | 8.76 | 5.82 | 2.83 | 1.06 | 1.04 | 1.43 | 1.20 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (166.50) | (166.50) | (21.02) | (11.59) | (5.68) | (5.23) | (7.32) | (5.47) |
P/B ratio |
— | 0.00 | 0.00 | 4.50 | 1.87 | 3.55 | 35.00 | 2.71 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 | 5.44 | 2.14 | 10.29 | 0.00 | 4.58 | 0.00 |
EV/Sales |
— | 8.75 | 8.75 | 4.53 | 1.49 | 0.99 | 1.08 | 1.16 | 1.59 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (15.15) | (15.15) | (10.41) | (1.60) | (0.81) | (1.24) | (1.37) | (1.81) |
EV/FCF |
— | (14.75) | (14.75) | (10.20) | (1.39) | (0.78) | (1.16) | (1.31) | (1.57) |
Quick Ratio |
— | 0.86 | 0.16 | 2.52 | 3.43 | 0.58 | 0.25 | 1.34 | 0.20 |
Current Ratio |
— | 0.87 | 0.22 | 2.60 | 3.64 | 0.80 | 0.34 | 1.50 | 0.24 |
Net Debt/EBITDA |
— | 0.07 | (0.33) | 1.49 | 1.16 | 0.05 | 0.10 | 0.59 | (0.37) |
Debt/Assets |
0.00% | 8.37% | 49.12% | 5.09% | 3.75% | 17.59% | 0.00% | 0.00% | 35.07% |
Debt/Equity |
— | 0.13 | (1.26) | 0.08 | 0.05 | 0.50 | 0.00 | 0.00 | (5.69) |
Asset Turnover |
— | 0.92 | 1.45 | 0.79 | 0.57 | 0.68 | 1.13 | 1.16 | 0.86 |
Operating CF/Net income |
— | 0.57 | 0.45 | 0.32 | 0.78 | 0.82 | 0.88 | 1.14 | 0.72 |
Capex/Depreciation |
— | 0.00 | (0.23) | (0.17) | (3.27) | (1.38) | (1.29) | (0.98) | (1.79) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (1,002.20%) | (1,248.00%) | (257.45%) | (95.57%) | (157.19%) | (521.22%) | (266.25%) | (648.99%) | |
| — | (230.11%) | (149.21%) | (109.42%) | (68.75%) | (100.59%) | (111.11%) | (85.62%) | (104.71%) | |
ROIC |
— | 0.00% | (2,225.84%) | (752,500.00%) | (459.22%) | (423.39%) | 0.00% | (412.15%) | (237.15%) |
Return on Tangible Assets |
— | (941.85%) | 196.89% | (133.99%) | (89.61%) | (1,408.45%) | 897.16% | (191.80%) | 213.09% |
Average Days of Receivables |
— | 57.29 | 30.63 | 42.32 | 37.16 | 10.41 | 5.34 | 10.44 | 33.08 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 275.19% | 162.23% | 140.85% | 185.62% | 214.56% | 180.76% | 130.46% | 166.98% |
Intangible Assets out of Total Assets |
0.00 | 0.60 | 0.45 | 0.12 | 0.09 | 0.23 | 0.30 | 0.21 | 0.50 |
Share Based Compensation of Revenue |
— | 0.00% | 18.11% | 46.81% | 17.23% | 19.39% | 13.98% | 5.35% | 3.79% |
Graham Net Nets |
— | 0.03 | 0.03 | 0.16 | 0.40 | (0.21) | (0.55) | 0.01 | (1.07) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.65 |
Earnings Yield |
— | (5.25%) | (5.25%) | (15.99%) | (43.56%) | (141.89%) | (93.64%) | (67.83%) | (101.97%) |
Free Cash Flow Yield |
— | (6.77%) | (6.77%) | (7.63%) | (37.95%) | (120.38%) | (88.63%) | (61.57%) | (84.41%) |
Revenue per Share |
— | 5.21 | 23.10 | 25.38 | 19.88 | 17.40 | 11.32 | 2.99 | 1.70 |
Operating CF per Share |
— | (7.45) | (10.83) | (11.03) | (18.53) | (21.27) | (9.80) | (2.53) | (1.49) |
Capex per Share |
— | 0.00 | (0.36) | (0.23) | (2.82) | (1.00) | (0.66) | (0.11) | (0.23) |
Free Cash Flow per Share |
— | (7.45) | (11.18) | (11.27) | (21.35) | (22.27) | (10.46) | (2.64) | (1.71) |
Cash per Share |
— | 1.72 | 0.95 | 35.37 | 28.29 | 3.82 | 1.35 | 1.25 | 0.20 |
Shareholders Equity per Share |
— | 7.55 | (5.97) | 32.86 | 30.07 | 5.21 | 0.34 | 1.58 | (0.15) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 7.55 | (5.97) | 32.86 | 30.07 | 5.21 | 0.34 | 1.58 | (0.15) |
Free Cash Flow |
— | (5.42) | (5.52) | (5.80) | (18.13) | (20.51) | (12.75) | (13.26) | (17.60) |
Working Capital |
— | (0.28) | (7.11) | 12.55 | 19.82 | (1.39) | (4.83) | 2.50 | (13.69) |
Capital Expenditures |
— | (1.25) | (0.18) | (0.12) | (2.40) | (0.92) | (0.80) | (0.57) | (2.34) |
Net Current Asset Value |
— | (0.83) | (8.51) | 11.98 | 19.17 | (3.49) | (7.86) | 0.14 | (22.32) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.02 | 0.01 | 0.14 | 0.06 | 0.06 | 0.04 | 0.13 |
Net Profit Margin |
— | (248.90%) | (103.17%) | (137.67%) | (120.15%) | (148.81%) | (98.42%) | (74.09%) | (121.37%) |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.48 | 0.66 | 0.82 | 0.26 | 0.22 | 0.19 | 0.18 | 0.35 |
Cash ROIC |
— | (90.11%) | (524.36%) | (17.99%) | (36.51%) | (211.21%) | (742.94%) | (112.58%) | (204.49%) |
Accounts Receivable Turnover |
— | 4.89 | 14.69 | 10.58 | 10.44 | 14.73 | 41.88 | 47.57 | 17.35 |
Accounts Payable Turnover |
— | 2.17 | 3.51 | 2.85 | 5.03 | 5.15 | 3.11 | 3.71 | 4.97 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 102.26 | 144.53 | 107.45 | 78.44 | 85.76 | 141.58 | 66.66 | 88.80 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.78 | 0.78 | 1.24 | 1.62 | 1.09 | 0.33 | 0.32 | 1.01 |
Average Payables |
— | 0.78 | 0.78 | 0.93 | 0.85 | 1.17 | 1.78 | 1.62 | 1.39 |
Average Assets |
— | 4.10 | 7.88 | 16.44 | 29.51 | 23.70 | 12.23 | 13.01 | 20.22 |
Average Common Equity |
— | 0.94 | 0.94 | 6.99 | 21.23 | 15.17 | 2.61 | 4.18 | 3.26 |
Columns are period end dates